
1. j virol. 1999 jul;73(7):5637-45.

identification multiple protective epitopes (protectopes) central
conserved domain prototype human respiratory syncytial virus g protein.

plotnicky-gilquin h(1), goetsch l, huss t, champion t, beck a, haeuw jf, nguyen
tn, bonnefoy jy, corvaïa n, power uf.

author information: 
(1)centre d'immunologie pierre fabre, 74164 saint-julien-en-genevois cedex,
france.

a recombinant fusion protein (bbg2na) comprising central conserved domain 
the respiratory syncytial virus subgroup (rsv-a) (long) g protein (residues 130
to 230) albumin binding domain streptococcal protein g shown
previously protect mouse upper (urt) lower (lrt) respiratory tracts
against intranasal rsv challenge (u. f. power, h. plotnicky-gilquin, t. huss, a. 
robert, m. trudel, s. stahl, m. uhlén, t. n. nguyen, h. binz, virology
230:155-166, 1997). panels monoclonal antibodies (mabs) synthetic peptides
were generated facilitate dissection structural elements domain
implicated protective efficacy. mabs recognized native rsv-a antigens, and
five linear b-cell epitopes identified; mapped residues 152 163,
165 172, 171 187 (two overlapping epitopes), 196 204, thereby
covering highly conserved cysteine noose domain. antibody passive-transfer
and peptide immunization studies revealed epitopes implicated in
protection lrt, likely urt, rsv-a challenge. pepscan
analyses anti-rsv-a anti-bbg2na murine polyclonal sera revealed
lower-level epitope usage within central conserved region former,
suggesting diminished immunogenicity implicated epitopes context of
the whole virus. however, pepscan analyses rsv-seropositive human sera
revealed murine b-cell protective epitopes (protectopes) that
mapped central conserved domain recognized man. these
murine protectopes also implicated human lrt protection, clustering
around highly conserved cysteine noose region important
implications development rsv vaccines.

doi: 10.1128/jvi.73.7.5637-5645.1999 
pmcid: pmc112622
pmid: 10364313  [indexed medline]

